{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:18:23Z","timestamp":1790889503938,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was funded by internal resources of Sant\u00e9 Publique France."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rift Valley Fever (RVF) is a zoonosis that affects large parts of Africa and the Arabian Peninsula. RVF virus (RVFV) is transmitted to humans through contacts with infected animals, animal products, mosquito bites or aerosols. Its pathogenesis in humans ranges from asymptomatic forms to potentially deadly haemorrhagic fevers, and the true burden of human infections during outbreaks is generally unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We build a model fitted to both passive surveillance data and serological data collected throughout a RVF epidemic that occurred in Mayotte Island in 2018\u20132019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We estimate that RVFV infected 10,797 (95% CrI 4,728\u201316,127) people aged \u226515\u2009years old in Mayotte during the entire outbreak, among which only 1.2% (0.67%\u20132.2%) were reported to the syndromic surveillance system. RVFV IgG seroprevalence in people \u226515\u2009years old was estimated to increase from 5.5% (3.6%\u20137.7%) before the outbreak to 12.9% (10.4%\u201316.3%) thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that a large part of RVFV infected people present subclinical forms of the disease and\/or do not reach medical care that could lead to their detection by the surveillance system. This may threaten the implementation of exhaustive RVF surveillance and adequate control programs in affected countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-022-00230-4","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:05:04Z","timestamp":1671613504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reconstructing Mayotte 2018\u201319 Rift Valley Fever outbreak in humans by combining serological and surveillance data"],"prefix":"10.1038","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8531-1614","authenticated-orcid":false,"given":"Jonathan","family":"Bastard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume Andr\u00e9","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Parenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssouf","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Dommergues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Paireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3977-8966","authenticated-orcid":false,"given":"Nathana\u00ebl","family":"Hoz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ruello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Grard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-196X","authenticated-orcid":false,"given":"Rapha\u00eblle","family":"M\u00e9tras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-9267","authenticated-orcid":false,"given":"Harold","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"230_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25833-8","volume":"12","author":"WSD Tennant","year":"2021","unstructured":"Tennant, W. S. D. et al. Modelling the persistence and control of Rift Valley fever virus in a spatially heterogeneous landscape. Nat. Commun. 12, 5593 (2021).","journal-title":"Nat. Commun."},{"key":"230_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2460\/javma.234.7.883","volume":"234","author":"BH Bird","year":"2009","unstructured":"Bird, B. H., Ksiazek, T. G., Nichol, S. T. & MacLachlan, N. J. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234, 883\u2013893 (2009).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"230_CR3","doi-asserted-by":"crossref","unstructured":"Bron, G. M. et al. Over 100\u2009years of Rift Valley fever: a patchwork of data on pathogen spread and spillover. Pathog. Basel Switz. 10, 708 (2021).","DOI":"10.3390\/pathogens10060708"},{"key":"230_CR4","unstructured":"WHO. WHO Fact Sheet on Rift Valley Fever. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rift-valley-fever (2018)."},{"key":"230_CR5","first-page":"105","volume":"73","author":"WHO.","year":"1998","unstructured":"WHO. An outbreak of Rift Valley Fever, Eastern Africa, 1997\u20131998\u2009=\u2009Une flamb\u00e9e de fi\u00e8vre de la vall\u00e9e du Rift en Afrique orientale, 1997\u20131998. Wkly. Epidemiol. Rec. Relev\u00e9 \u00c9pid\u00e9miologique Hebd. 73, 105\u2013109 (1998).","journal-title":"Wkly. Epidemiol. Rec. Relev\u00e9 \u00c9pid\u00e9miologique Hebd."},{"key":"230_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/zph.12153","volume":"62","author":"M Peyre","year":"2015","unstructured":"Peyre, M. et al. A systematic scoping study of the socio-economic impact of Rift valley fever: research gaps and needs. Zoonoses Public Health 62, 309\u2013325 (2015).","journal-title":"Zoonoses Public Health"},{"key":"230_CR7","doi-asserted-by":"crossref","unstructured":"van Leeuwen, L. P. M. et al. Exotic viral hepatitis: a review on epidemiology, pathogenesis, and treatment. J. Hepatol. 77, 1431\u20131443 (2022).","DOI":"10.1016\/j.jhep.2022.06.031"},{"key":"230_CR8","unstructured":"CDC. Signs and Symptoms\u2014Rift Valley Fever. https:\/\/www.cdc.gov\/vhf\/rvf\/symptoms\/index.html (2020)."},{"key":"230_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","volume":"3","author":"T Ikegami","year":"2011","unstructured":"Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493\u2013519 (2011).","journal-title":"Viruses"},{"key":"230_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21788-y","volume":"12","author":"AD Henderson","year":"2021","unstructured":"Henderson, A. D. et al. Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji. Nat. Commun. 12, 1671 (2021).","journal-title":"Nat. Commun."},{"key":"230_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.pt.2019.01.009","volume":"35","author":"S Cauchemez","year":"2019","unstructured":"Cauchemez, S., Hoze, N., Cousien, A. & Nikolay, B. & ten bosch, Q. How modelling can enhance the analysis of imperfect epidemic data. Trends Parasitol 35, 369\u2013379 (2019).","journal-title":"Trends Parasitol"},{"key":"230_CR12","doi-asserted-by":"publisher","first-page":"e0004840","DOI":"10.1371\/journal.pntd.0004840","volume":"10","author":"K Dellagi","year":"2016","unstructured":"Dellagi, K. et al. Serological evidence of contrasted exposure to Arboviral infections between islands of the Union of Comoros (Indian Ocean). PLoS Negl. Trop. Dis. 10, e0004840 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"230_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12917-020-02455-8","volume":"16","author":"NB Alhaji","year":"2020","unstructured":"Alhaji, N. B. et al. Seropositivity and associated intrinsic and extrinsic factors for Rift Valley fever virus occurrence in pastoral herds of Nigeria: a cross sectional survey. BMC Vet. Res. 16, 243 (2020).","journal-title":"BMC Vet. Res."},{"key":"230_CR14","doi-asserted-by":"publisher","first-page":"e0005731","DOI":"10.1371\/journal.pntd.0005731","volume":"11","author":"EAJ Cook","year":"2017","unstructured":"Cook, E. A. J. et al. The sero-epidemiology of Rift Valley fever in people in the Lake Victoria Basin of western Kenya. PLoS Negl. Trop. Dis. 11, e0005731 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"230_CR15","doi-asserted-by":"publisher","first-page":"e74192","DOI":"10.1371\/journal.pone.0074192","volume":"8","author":"T Lernout","year":"2013","unstructured":"Lernout, T. et al. Rift Valley fever in humans and animals in Mayotte, an Endemic situation? PLoS One 8, e74192 (2013).","journal-title":"PLoS One"},{"key":"230_CR16","doi-asserted-by":"publisher","first-page":"24567","DOI":"10.1073\/pnas.2004468117","volume":"117","author":"R M\u00e9tras","year":"2020","unstructured":"M\u00e9tras, R. et al. Estimation of Rift Valley fever virus spillover to humans during the Mayotte 2018\u20132019 epidemic. Proc. Natl. Acad. Sci. 117, 24567\u201324574 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"230_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep39870","volume":"7","author":"M-M Olive","year":"2017","unstructured":"Olive, M.-M. et al. Reconstruction of Rift Valley fever transmission dynamics in Madagascar: estimation of force of infection from seroprevalence surveys using Bayesian modelling. Sci. Rep. 7, 39870 (2017).","journal-title":"Sci. Rep."},{"key":"230_CR18","unstructured":"INSEE. Recensement de la population de Mayotte en 2017. https:\/\/www.insee.fr\/fr\/statistiques\/3284395?sommaire=4199393 (2019)."},{"key":"230_CR19","doi-asserted-by":"publisher","first-page":"e0004783","DOI":"10.1371\/journal.pntd.0004783","volume":"10","author":"R M\u00e9tras","year":"2016","unstructured":"M\u00e9tras, R. et al. The Epidemiology of Rift valley fever in Mayotte: insights and perspectives from 11\u2009years of data. PLoS Negl. Trop. Dis. 10, e0004783 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"230_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3201\/eid2604.191147","volume":"26","author":"H Youssouf","year":"2020","unstructured":"Youssouf, H. et al. Rift Valley fever outbreak, Mayotte, France, 2018\u20132019. Emerg. Infect. Dis. 26, 769\u2013772 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"230_CR21","doi-asserted-by":"crossref","unstructured":"Ruello, M. & Richard, J. Enqu\u00eate de sant\u00e9 \u00e0 Mayotte 2019\u2014Unono Wa Maore. M\u00e9thode (Sant\u00e9 publique France, 2022).","DOI":"10.3917\/ehesp.raimo.2023.02.0003"},{"key":"230_CR22","unstructured":"INSEE. Register of Localized Buildings. https:\/\/www.insee.fr\/en\/metadonnees\/definition\/c1815 (2019)."},{"key":"230_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jviromet.2011.07.011","volume":"177","author":"R Williams","year":"2011","unstructured":"Williams, R. et al. Validation of an IgM antibody capture ELISA based on a recombinant nucleoprotein for identification of domestic ruminants infected with Rift Valley fever virus. J. Virol. Methods 177, 140\u2013146 (2011).","journal-title":"J. Virol. Methods"},{"key":"230_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jviromet.2004.11.020","volume":"124","author":"JT Paweska","year":"2005","unstructured":"Paweska, J. T., Burt, F. J. & Swanepoel, R. Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans. J. Virol. Methods 124, 173\u2013181 (2005).","journal-title":"J. Virol. Methods"},{"key":"230_CR25","doi-asserted-by":"publisher","first-page":"e0006460","DOI":"10.1371\/journal.pntd.0006460","volume":"12","author":"A Maurice","year":"2018","unstructured":"Maurice, A. et al. Rift valley fever viral load correlates with the human inflammatory response and coagulation pathway abnormalities in humans with hemorrhagic manifestations. PLoS Negl. Trop. Dis. 12, e0006460 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"230_CR26","doi-asserted-by":"publisher","first-page":"e0007747","DOI":"10.1371\/journal.pntd.0007747","volume":"13","author":"J Denis","year":"2019","unstructured":"Denis, J. et al. High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel. PLoS Negl. Trop. Dis. 13, e0007747 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"230_CR27","doi-asserted-by":"crossref","unstructured":"Peyrefitte, C. N. et al. Dengue Type 3 Virus, Saint Martin, 2003\u20132004. Emerg. Infect. Dis. 11, 757\u201361 (2005).","DOI":"10.3201\/eid1105.040959"},{"key":"230_CR28","doi-asserted-by":"publisher","first-page":"1800213","DOI":"10.2807\/1560-7917.ES.2019.24.8.1800213","volume":"24","author":"C Tong","year":"2019","unstructured":"Tong, C. et al. Tracking Rift Valley fever: from Mali to Europe and other countries, 2016. Eurosurveillance 24, 1800213 (2019).","journal-title":"Eurosurveillance"},{"key":"230_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29999-y","volume":"8","author":"Y Kim","year":"2018","unstructured":"Kim, Y. et al. Livestock trade network: potential for disease transmission and implications for risk-based surveillance on the island of Mayotte. Sci. Rep. 8, 11550 (2018).","journal-title":"Sci. Rep."},{"key":"230_CR30","doi-asserted-by":"publisher","first-page":"e0009202","DOI":"10.1371\/journal.pntd.0009202","volume":"15","author":"Y Kim","year":"2021","unstructured":"Kim, Y. et al. The role of livestock movements in the spread of Rift Valley fever virus in animals and humans in Mayotte, 2018\u201319. PLoS Negl. Trop. Dis. 15, e0009202 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"230_CR31","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1016\/j.vaccine.2015.08.020","volume":"33","author":"KL Mansfield","year":"2015","unstructured":"Mansfield, K. L. et al. Rift Valley fever virus: a review of diagnosis and vaccination, and implications for emergence in Europe. Vaccine 33, 5520\u20135531 (2015).","journal-title":"Vaccine"},{"key":"230_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/v8050145","volume":"8","author":"WC Wilson","year":"2016","unstructured":"Wilson, W. C. et al. Experimental infection of Calves by two Genetically-distinct strains of Rift Valley fever virus. Viruses 8, 145 (2016).","journal-title":"Viruses"},{"key":"230_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jviromet.2011.11.025","volume":"179","author":"BS Drolet","year":"2012","unstructured":"Drolet, B. S. et al. Development and evaluation of one-step rRT-PCR and immunohistochemical methods for detection of Rift Valley fever virus in biosafety level 2 diagnostic laboratories. J. Virol. Methods 179, 373\u2013382 (2012).","journal-title":"J. Virol. Methods"},{"key":"230_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jviromet.2008.04.007","volume":"151","author":"J N\u00e4slund","year":"2008","unstructured":"N\u00e4slund, J. et al. Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR. J. Virol. Methods 151, 277\u2013282 (2008).","journal-title":"J. Virol. Methods"},{"key":"230_CR35","unstructured":"Plummer, M., Stukalov, A., Denwood, M. & Plummer, M. M. Package \u2018rjags\u2019 (Vienna Austria, 2016)."},{"key":"230_CR36","doi-asserted-by":"publisher","first-page":"e0003536","DOI":"10.1371\/journal.pntd.0003536","volume":"9","author":"RD Sumaye","year":"2015","unstructured":"Sumaye, R. D. et al. Inter-epidemic Acquisition of Rift Valley Fever Virus in humans in Tanzania. PLoS Negl. Trop. Dis. 9, e0003536 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"230_CR37","doi-asserted-by":"crossref","unstructured":"Paw\u0119ska, J. T. et al. Rift Valley fever virus seroprevalence among humans, Northern KwaZulu-Natal Province, South Africa, 2018\u20132019. Emerg. Infect. Dis. 27, 107 (2021).","DOI":"10.3201\/eid2712.210643"},{"key":"230_CR38","doi-asserted-by":"crossref","first-page":"e06093","DOI":"10.2903\/j.efsa.2020.6041","volume":"18","author":"SS Nielsen","year":"2020","unstructured":"Nielsen, S. S. et al. Rift Valley Fever: risk of persistence, spread and impact in Mayotte (France). EFSA J 18, e06093 (2020).","journal-title":"EFSA J"},{"key":"230_CR39","unstructured":"CDC. Diagnosis\u2014Rift Valley Fever. https:\/\/www.cdc.gov\/vhf\/rvf\/diagnosis\/index.html (2020)."},{"key":"230_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1473-3099(18)30164-6","volume":"18","author":"TR Shoemaker","year":"2018","unstructured":"Shoemaker, T. R. et al. Impact of enhanced viral haemorrhagic fever surveillance on outbreak detection and response in Uganda. Lancet Infect. Dis. 18, 373\u2013375 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"230_CR41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41586-020-03095-6","volume":"590","author":"G Pullano","year":"2021","unstructured":"Pullano, G. et al. Underdetection of cases of COVID-19 in France threatens epidemic control. Nature 590, 134\u2013139 (2021).","journal-title":"Nature"},{"key":"230_CR42","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1126\/science.1176062","volume":"324","author":"C Fraser","year":"2009","unstructured":"Fraser, C. et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324, 1557\u20131561 (2009).","journal-title":"Science"},{"key":"230_CR43","doi-asserted-by":"publisher","unstructured":"Barber, R. M. et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(22)00484-6 (2022).","DOI":"10.1016\/S0140-6736(22)00484-6"},{"key":"230_CR44","doi-asserted-by":"publisher","unstructured":"JonathanBas. JonathanBas\/RVF_Mayotte: Mayotte RVF Outbreak. https:\/\/doi.org\/10.5281\/zenodo.7343566 (Zenodo, 2022).","DOI":"10.5281\/zenodo.7343566"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00230-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00230-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00230-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T17:02:44Z","timestamp":1728579764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00230-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["230"],"URL":"https:\/\/doi.org\/10.1038\/s43856-022-00230-4","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"15 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interest: Rapha\u00eblle M\u00e9tras is an Editorial Board Member for Communications Medicine, but was not involved in the editorial review or peer review, nor in the decision to publish this article. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}